Neophyr (Nitric Oxide)

Nitric Oxide, the active ingredient in Neophyr, is a vasodilator presented as a medical gas for inhalation use. It is employed to treat pulmonary hypertension and neonatal persistent pulmonary hypertension by relaxing pulmonary vascular smooth muscle. GNH USA supplies Neophyr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Neophyr is an inhaled pulmonary vasodilator indicated for conditions affecting the pulmonary circulation. - Pulmonary hypertension: lowers pulmonary arterial pressure and improves functional capacity in adult patients. - Neonatal persistent pulmonary hypertension: enhances oxygenation and reduces the need for extracorporeal support in newborns.

Neophyr may be associated with several adverse reactions.

Common Side Effects: - Cough or throat irritation - Headache - Dizziness or light‑headedness - Nausea or vomiting - Flushing or warmth sensation - Mild hypotension

Serious or Rare Side Effects: - Methemoglobinemia - Severe hypotension or cardiovascular collapse - Rebound pulmonary hypertension upon abrupt discontinuation - Bleeding complications related to platelet inhibition - Infection from contaminated delivery system - Pulmonary edema

When using Neophyr, clinicians should observe specific safety measures. - Monitor blood pressure: watch for hypotensive episodes during and after inhalation. - Assess methemoglobin levels: especially in patients with anemia or G6PD deficiency. - Use cautiously in neonates: adjust delivery concentration and duration as per neonatal protocols. - Avoid concurrent use with other nitric‑oxide donors: risk of additive vasodilation. - Review anticoagulant therapy: increased bleeding risk may occur. - Store at ambient temperature: keep cylinder upright, protect from heat and direct sunlight.

Neophyr can interact with several drug classes, requiring attention to dosing and monitoring.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): may cause profound hypotension. - Other inhaled nitric‑oxide donors: additive vasodilatory effect leading to severe hypotension. - Systemic vasodilators (e.g., nitroglycerin, hydralazine): risk of excessive blood pressure drop. - Methylene blue: antagonizes nitric‑oxide activity, reducing therapeutic effect.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., heparin, warfarin): potential for increased bleeding. - Inhaled anesthetics (e.g., sevoflurane, isoflurane): may enhance hypotensive response. - Bronchodilators (e.g., albuterol): monitor for synergistic pulmonary effects.